Monday , May 21 2018
Home / Business News

Business News

Janssen Halts Development of its BACE Inhibitor for Alzheimer’s Disease Due to Liver Safety Concerns

Titusville, United States, May 17, 2018 – At Janssen, the safety and well-being of people who participate in our clinical trials are of utmost importance to us. For the past several years, we have been studying an investigational drug called a BACE inhibitor. The goal of this research is to slow …

Read More »

Eiger Expands License Agreement with Merck for Investigational Lonafarnib for Treatment of Rare and Fatal Genetic Disease

PALO ALTO, Calif., May 16, 2018 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside the United States and Canada, to include rights to develop …

Read More »

Emulate and AstraZeneca Partner to Develop Organs-on-Chips Technology to Improve Prediction of Safety and Efficacy or Drug Candidates

BOSTON–(BUSINESS WIRE)–Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization. As part of the agreement, Emulate plans to co-locate scientists within AstraZeneca’s laboratories. The aim of this agreement is …

Read More »

TapImmune and Marker Therapeutics Enter into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

JACKSONVILLE, Florida – May 15, 2018 – TapImmune Inc. (NASDAQ: TPIV) (“TapImmune”) today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform. The proposed transaction will be a merger-of-equals under which the …

Read More »

Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement. “With a successful track record …

Read More »

Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis

mina SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to …

Read More »

Medigene Expands T-Cell Receptor Deal with Bluebird bio to up to $1.5 Billion

Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, today announced the significant expansion of its successful strategic alliance with bluebird bio, a leader in gene and cell therapies, focusing on the research and development of T cell receptor-modified T cell (TCR-T) immunotherapies for the treatment of cancer. “We are delighted to …

Read More »

Lilly to Expand Oncology Pipeline through its Acquisition of AurKa Pharma

INDIANAPOLIS, May 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma …

Read More »

Lilly Agrees to Acquire ARMO BioSciences for $1.6 Billion, Bolstering its Immuno-Oncology Pipeline

INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to …

Read More »

Takeda to Acquire Shire for $62 Billion

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and Shire plc (LON: SHP) (“Shire”) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. Under the terms …

Read More »